Norfloxacin: review of safety studies.
The tolerability profile of norfloxacin, the first of a new generation of fluoroquinolone carboxylic acid antibacterials, has been defined in numerous laboratory animal and human trials. Whether administered for moderate or protracted periods, norfloxacin has been relatively safe in animals over a wide range of doses. There has been no evidence of a teratogenic effect in any of the animal species tested (rat, rabbit, mouse, monkey) at six to 50 times the human dose (400 mg twice daily). However, norfloxacin has been shown to produce embryonic loss in monkeys when given in doses 10 times the maximal human dose, resulting in peak plasma levels that are two to three times those obtained in humans. Although there are no adequate and well-controlled studies in pregnant women, norfloxacin is not recommended for use in this population because it, like other drugs in this class, causes arthropathy in immature animals. In animals, norfloxacin is neither mutagenic nor carcinogenic, and, in clinical trials, norfloxacin-related adverse experiences have been uncommon. Those that have occurred have been generally mild, requiring discontinuation of therapy in less than 1 percent of patients. The most frequently reported side effects have been nausea, dyspepsia, headache, and dizziness. Administration of 400 mg of norfloxacin at two or three times a day has been associated with reasonably good gastrointestinal tolerance.
D000818:Animals; D002273:Carcinogens; D004341:Drug Evaluation; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D009153:Mutagens; D009422:Nervous System Diseases / Q000139:chemically induced; D009643:Norfloxacin / Q000009:adverse effects / Q000633:toxicity*; D013723:Teratogens
D002273:Carcinogens; D009153:Mutagens; D013723:Teratogens; D009643:Norfloxacin